Twelfth International Symposium on Regional Cancer Therapies
Snowbird Ski and Summer Resort
Snowbird, UT

February 18–20, 2017

Sponsored by
David C. Koch Regional Cancer Therapy Center
and
University of Pittsburgh School of Medicine Center for Continuing Education in the Health Sciences
and
UPMC CancerCenter

In Collaboration with
The University of Maryland
Marlene and Stewart Greenebaum Cancer Center
The Medical College of Wisconsin Cancer Center

Course Co-Directors
H. Richard Alexander, MD
Professor of Surgery
University of Maryland School of Medicine
Baltimore, Maryland

David L. Bartlett, MD
Professor of Surgery
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Robert P. Edwards, MD
Professor, Obstetrics, Gynecology and Reproductive Sciences
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

T. Clark Gamblin, MD, MS, MBA
Stuart D. Wilson Chair in Surgical Oncology
Chief, Division of Surgical Oncology
Professor of Surgery
Medical College of Wisconsin
Milwaukee, Wisconsin

In Partnership with the Society of Surgical Oncology
Intent and Overview

This course is designed to cover the most recent advances in cancer therapy that are primarily of a regional focus, such as gastrointestinal, intraperitoneal, hepatic, ovarian and thoracic. Upon completion of the activity, learners from several disciplines should be able to discuss the latest regional therapies in surgical oncology.

Who Should Attend

This course is designed for physicians and nurses practicing in the areas of Medical, Surgical, Thoracic and Gynecologic Oncology and Gastroenterology.

Continuing Education Credit

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this live activity for a maximum of 20.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Other health care professionals are awarded 2.0 continuing education units (CEU’s) which are equal to 20.5 contact hours.

Special Needs

Participation by all individuals is encouraged. Advance notification of any special needs will help us provide better service. Please notify us of your needs at least two weeks in advance of the program by calling Maureen Hewko at (412) 623-5993.

Schedule – Saturday, February 18, 2017

6:45 am  Registration and Breakfast
7:00 am  Welcome

Moderators: Giorgos Karakousis, MD and John Kane, MD

7:15 am  Oncologic Outcomes Following Cytoreductive Surgery and HIPEC
For “Acellular Mucin”
Haroon Choudry, MD, et. al.

7:30 am  Clinical Management of Early Stage Low-Grade Appendiceal Mucinous Neoplasms (LAMN): The “Watch and Wait” Strategy
Marcello Guagli, MD, et. al.

7:45 am  Cancer-related Variants in Mucinous Appendiceal Neoplasms Detected by High Resolution Targeted Amplicon Sequencing
William LaFramboise, MD, et. al.

8:00 am  Outcome of Low-Grade Mucinous Appendiceal Neoplasms with Remote Acellular Mucinous Peritoneal Deposits
Campbell Roxburgh, MD, et. al.

8:15 am  When to and When Not to Perform a Right Colon Resection with Mucinous Appendiceal Neoplasms
Paul Sugarbaker, MD, et. al.

8:30 am  PCI is not Predictive of Survival after Complete CRS/HIPEC in Carcinomatosis from High Grade Appendiceal Primaries
Konstantinos Votanopoulos, MD, et. al.

8:45 am  Break with Refreshments/Exhibitors

Moderators: Fabian Johnston, MD, and Charles Staley, MD

9:00 am  Patterns of Recurrent Disease Following Complete Cytoreduction and HIPEC in Patients with Peritoneal Carcinomatosis from Colorectal Adenocarcinoma
Yael Feferman, MD, et. al.
9:15 am A Survey of Physician Attitudes and Practice Patterns Regarding Treatment of Patients with Peritoneal Metastases
Tyler Bernaiche, MD, et. al.

9:30 am Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single Center Series of 244 Patients Treated by CRS/HIPEC
Dario Baratti, MD, et. al.

9:45 am GUEST LECTURE
The 10 Best From PSOGI 2016
Paul Sugarbaker, MD

10:15 am Break Until Evening Session

3:30 pm POSTER VIEWING

Moderators: Yuman Fong, MD and JF Geschwind, MD

4:30 pm Liver Resection Synchronous with Hepatic Arterial Infusion Pump (HAIP) for Colorectal Cancer Liver Metastases: Results alone or with Liver Resection
Ioannis Konstantinidis, MD, et. al.

4:45 pm Robotic Hepatic Arterial Infusion Pump Placement
Motaz Qadan, MD, et. al.

5:00 pm Percutaneous Hepatic Perfusion (PHP) for Unresectable Isolated Hepatic Metastases from Sarcoma
Cristina O’Donoghue, MD, et. al.

5:15 pm Dose Determination of Doxorubicin Administered During DEB-TACE by Spectral Measurements
Venkateswara Gogineni, MD, et. al.

5:30 pm Irinotecan-eluting LC Bead-M1 (DEBIRI-M1) for Patients with Liver Metastases from Colorectal Cancer: A Phase II Single-Center Study
Julius Chapiro, MD, et. al.

5:45 pm Intra-Arterial Therapy for Multifocal Intrahepatic Cholangiocarcinoma Results in Equivalent Survival Compared with Surgical Resection
Paul Wright, MD, et. al.

6:00 pm Transarterial Chemoembolization in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Systematic Review and Meta-Analysis
Jack Silva, MD, et. al.

6:15 pm A Novel 3-Dimensional Electromagnetic Guidance System (EMPRINT™) Increases Microwave Antenna Placement Accuracy
Amit Sastry, MD, et. al.

6:30 pm Light Dinner/Exhibitors

Moderators: James Pingpank, MD and Michael D’Angelica, MD

6:45 pm Salvage Therapy with Y-90 Radio-Embolization for Patients with Hepatic Metastases from Neuroendocrine Tumors: A Retrospective Review
Rushin Brahmbhatt, MD, et. al.

7:00 pm Recurrence Patterns Following Irreversible Electroporation for Hepatic Malignancies
Russell Langan, MD, et. al.

7:15 pm Operative Microwave Ablation for Hepatocellular Carcinoma: A Single Center Retrospective Review of 219 Patients
Erin Baker, MD, et. al.

7:30 pm Development of a Radiofrequency Ablation Platform in a Clinically Relevant Murine Model of Hepatocellular Cancer
Eric Kimchi, MD, et. al.

7:45 pm Safety and Efficacy of Infusional Melphalan for Patients with Hepatic Insufficiency Secondary to High Volume Metastatic Uveal Melanoma
Brian Boone, MD, et. al.

8:00 pm Debate: TACE/Y90 vs. Bland Embolization for Hepatocellular Carcinoma
JF Geschwind, MD and Karen Brown, MD

8:30 pm Evening Session Adjournment

8:45 pm MEET THE PROFESSORS RECEPTION
Presentation of the Gabriella Graham Patient Advocate Award
Schedule – Sunday, February 19, 2017

6:45 am Registration and Breakfast

7:00 am Welcome

Moderators: Matthew Holtzman, MD and J. Andrea McCart, MD

7:15 am A Multicentric PSOGI Study on Peritoneal Mesotheliomas With Uncertain Malignant Potential
Shigeki Kusamura, MD, et. al.

7:30 am Operative Management of 200 Patients with Diffuse Malignant Peritoneal Mesothelioma: Intention to Treat with Cytoreduction and IP Chemotherapy
Michael Kluger, MD, et. al.

7:45 am Is Cytoreductive Surgery with HIPEC Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from Peritoneal Surface Oncology Group International Registry
Konstantinos Votanopoulos, MD, et. al.

8:00 am Predictors and Outcomes of Surgical Treatments in Patients with Diffuse Malignant Peritoneal Mesothelioma-Analysis of Data from the National Cancer Database
Lana Bijelic, MD, et. al.

8:15 am Debate: Upfront Systemic Therapy (Chemo/Immunotherapy) Should Be Used in Patients with Epithelioid Mesothelioma at the Risk of Incomplete Cytoreduction
PRO: Garrett Nash, MD  CON: H. Richard Alexander, MD

8:45 am Break with Refreshments/Exhibitors

Moderators: James Cusack, MD and Daniel Labow, MD

9:00 am Institutional Experience with Ostomies Created During Cytoreductive Surgery and HIPEC
Sam Pakraftar, MD, et. al.

9:15 am Correlation of Perioperative Coagulopathy, Hyperlactatemia, and Fresh Frozen Plasma Transfusion with Post-Operative Adverse Outcome Following CRS with HIPEC
Chukwuemeka Ihemelandu, MD, et. al.

9:30 am GUEST LECTURE
Optimal Management of Peritoneal Carcinomatosis from Colorectal Cancer. A Medical Oncologist’s Perspective
John Marshall, MD

10:00 am GUEST LECTURE
Landscape of Metastatic Colon Cancer and Advances in Therapies
Al Benson, MD

10:30 am DISCUSSION
Moderator: Edward Levine, MD
Panel: Nathan Bahary, MD, H. Richard Alexander, MD, Paul Sugarbaker, MD, John Marshall, MD, and Al Benson, MD

11:00 am Break Until Evening Session

Noon NON-CME EVENT
Clinical Considerations for Treatment in Advanced Melanoma
Jonathan Zager, MD

3:30 pm POSTER VIEWING

Moderators: Jonathan Zager, MD and Douglas Tyler, MD

4:30 pm Percutaneous Hepatic Perfusion (PHP) for Unresectable Metastatic Ocular Melanoma to the Liver: A Multi-Institutional Report of Outcomes
Alexandra Gangi, MD, et. al.

4:45 pm Exploring Immunologic Aspects of Regional Therapy in Melanoma
Jennifer Perone, MD, et. al.

5:00 pm The Growing Trend of Immune and Targeted Therapy in In-Transit Melanoma
Darren Bryan, MD, et. al.

5:15 pm Isolated Limb Perfusion and Infusion for Locally Advanced Extremity Soft Tissue Sarcoma: A Contemporary Systemic Review and Meta-Analysis
Madalyn Neuwirth, MD, et. al.
Schedule – Monday, February 20, 2017

6:45 am  Registration and Breakfast

Moderators: Joseph Skitzki, MD and Michael Kluger, MD

7:00 am  Is There an Opportunity for Prevention or Early Diagnosis of Peritoneal Malignancy from Appendiceal Neoplasms? An Analysis of Initial Patient Presentations
Matthew Furman, MD, et. al.

7:15 am  The Active Role of the Omentum in the Metastatic Process of GI Malignancies
Guy Lahat, MD, et. al.

7:30 am  Designing the Next Generation Oncolytic Vaccinia Virus for Peritoneal Carcinomatosis
J. Andrea McCart, MD, et. al.

7:45 am  Peritoneal Metastases from Endometrial Cancer Treated with CRS Combined with HIPEC: A Report on 33 Patients
Tommasso Cornali, MD, et. al.

8:00 am  Is Systemic Lymphadenectomy During Maximal Cytoreduction Plus HIPEC Worthwhile in Patients with Primary Ovarian Cancer and Diffuse Peritoneal Metastases?
Paolo Sammartino, MD, et. al.

8:15 am  GUEST LECTURE
Toward an Evidence-Based Rationale for Using Hyperthermia in Regional Cancer Therapies
Elizabeth Repasky, MD

8:45 am  Break and Exhibitors

Moderators: Jason Foster, MD and Steven Ahrendt, MD

9:00 am  Intra-abdominal Pressure During Closed System-HIPEC
Michael Goldenshluger, MD, et. al.

9:15 am  Peritoneal Disease is More Common than Nodal Disease in Patients With High-Grade Appendix Tumors Undergoing “Prophylactic” CRS And HIPEC
Akash Mehta, MD, et. al.

9:30 am  The Efficacy of CRS and HIPEC in Desmoplastic Small Round Cell Tumor: Results of a Phase 2 Trial
Brian Coakley, MD, et. al.

9:45 am  Use of Preoperative MRI for Selection of Patients with Moderate to Large Tumor Burden Being Considered for CRS and HIPEC
Russell Low, MD, et. al.

10:00 am  Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative CRS and HIPEC
Yue Li, MD, et. al.
10:15 am  A NSQIP Analysis of CRS/HIPEC Outcomes Compared to Other Major GI Surgeries
Richard Sleightholm, MD, et. al.

10:30 am  Patterns of Care and Trends in Postoperative Outcomes Among Patients Receiving HIPEC
Faiz Gani, MD, et. al.

10:45 am  Safety and Efficacy of an Enhanced Recovery after Surgery (ERAS) Pathway in Patients with Peritoneal Surface Malignancies
Joel Beane, MD, et. al.

11:00 am  Perioperative Impact of Goal-Directed Fluid Therapy after CRS and HIPEC
Whitney Guerrero, MD, et. al.

11:15 am  Moderators: Laura Lambert, MD and Jan Franko, MD

MINI PRESENTATIONS (5 minutes and 1 minute for discussion)

**Laparoscopic-Assisted CRS Plus HIPEC**
George Salti, MD, et. al.

**Rare Case Report of Serous Ascites and Diffuse Peritoneal Nodularity in a Healthy 43-year-old Patient**
Christopher Staley, MD, et. al.

**Outcomes of CRS in Patients Presenting with Massive Peritoneal Carcinomatosis**
Ali Khalifeh, MD, et. al.

**Routine Fecal Diversion is Unnecessary in Patients Undergoing CRS**
Leslie Anewenah, MD, et. al.

**Impact of Obesity on Surgical Outcome After CRS and HIPEC**
Carlos Chan, MD, et. al.

**Updates in Ovarian Cancer Trials**
Robert Edwards, MD

11:45 am  Announcement of Poster Winners

Noon  Conference Adjournment

---

**Poster Presentations**

1. ACS NSQIP Surgical Outcomes in HIPEC Based on Preoperative Hypoalbuminemia and BMI: What Carries the Most Weight? – Mazin Al-Kasspoolees, MD, et. al.

2. Diagnostic Laparoscopy is Effective in Evaluating Patients with PSM Prior to CRS and HIPEC – Danielle A. Bischof, MD, et. al.

3. CRS and Normothermic Intraperitoneal Chemotherapy (CRS/HIPC) in a Cirrhotic Patient with Signet Ring Cell Appendiceal Adenocarcinoma – Ea-sle Chang, MD, et. al.

4. Frailty Correlates with Postoperative Mortality and Major Morbidity after CRS with HIPEC – Konstantinos Choularias, MD, et. al.


6. An Unusual Progression of Signet-Ring Cell Carcinoma of the Appendix in a Caucasian Woman – Carlos Chan, MD, et. al.

7. Serum Mesothelin as a Circulating Marker of Diffuse Malignant Peritoneal Mesothelioma: Preliminary Study – Marcello Deraco, MD, et. al.

8. CRS and HIPEC as a Bridge to Systemic Chemotherapy – Laurence Diggs, MD, et. al.


11. Fluid Administration and Morbidity in CRS with HIPEC – Oliver Eng, MD, et. al.

12. Base Excess as a Predictor of Complications in CRS with HIPEC – Oliver Eng, MD, et. al.

13. Conflicting Data on Neutropenia Rates Following HIPEC with Mitomycin – C Yael Feferman, MD, et. al.


17. Selective Use of Diverting Ostomies is Safe in Patients Undergoing low Anterior Resection During CRS and HIPEC – Abdul Ayoub, MD, et. al.

18. Clinical Risk Factors and Biomarkers for Cancer Associated Venous Thromboembolism. A Predictive Model in Patients with Peritoneal Metastasis Treated with CRS and Perioperative Intraperitoneal Chemotherapy (POIC) – Chukwuemeka Ihemelandu, MD, et. al.


20. Opioid Consumption after HIPEC – Andrew Leitner, MD, et. al.
21. Failure to Rescue Following CRS and HIPEC – Patricio Polanco, et. al.
22. Deciduous Subtype of Diffuse Malignant Peritoneal Mesothelioma Presenting with Spontaneous Hemoperitoneum – Lindsey Reagin, MD, et. al.
23. Preoperative Bevacizumab Does Not Increase Complications Following CRS and HIPEC – Rebecca Marmor, MD, et. al.
24. Therapeutic Laparoscopy for Fertility Enhancement and Short to Medium Term Disease Control in Young Female Patients with Pseudomyxoma Peritonei of Appendiceal Origin – Akash Mehta, MD, et. al.
26. Age Complications Predict Deconditioning and Disposition Following CRS with HIPEC – Michael O’Leary, MD, et. al.
27. Investigating the Association between Perioperative Opioid Consumption and Survival in Children Undergoing CRS with HIPEC – Pascal Owusu-Agyemang, MD, et. al.
30. Complete Response in Peritoneal Metastasis from Gastric Cancer – Mihir Shah, MD, et. al.
32. Adenocarcinoma Ex-Goblet Cell Carcinoid of the Appendix is a Tumor of Intestinal Lineage and Mucinous Differentiation – Charles Staley, MD, et. al.
33. What to Expect When Starting a CRS/HIPEC Program at an Academic Institution – Alexander Stark, MD, et. al.
34. Implications of HIPEC Perfusion-Related Hyperglycemia – Camille Stewart, MD, et. al.
36. Is CRS with HIPEC Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from Peritoneal Surface Oncology Group International Registry – Konstantinos Votanopoulos, MD, et. al.
38. Obstruction-Free Survival Following Operative Intervention for Malignant Bowel Obstruction in Appendix Cancer – Rebecca Marmor, MD, et. al.
39. Hospital Free Days, a Novel Composite Endpoint, in Patients Undergoing CRS and HIPEC – Jesse Wright, MD, et. al.
40. Phase II Randomized Study on Tissue Distribution of Cisplatin According to Different Levels of Intra-Abdominal Pressure During HIPEC: Preliminary Results: ClinicalTrials.gov Identifier: NCT02949791 – Shigeki Kusamura, MD, et. al.
Invited Faculty

Steven Ahrendt, MD
Associate Professor of Surgery
University of Pittsburgh School of Medicine

Robert Andtbacka, MD
Associate Professor, Surgical Oncology
Department of Surgery
Salt Lake City, UT

Nathan Bahary, MD
Associate Professor of Medicine
University of Pittsburgh School of Medicine

Joel Baumgartner, MD
UCSD Moores Cancer Center
La Jolla, CA

Haroon Choudry, MD
Assistant Professor of Surgery
University of Pittsburgh School of Medicine

James Cusack, MD
Associate Professor of Surgery
Harvard Medical School
Boston, MA

Michael D’Angelica, MD
Memorial Sloan Kettering Cancer Center
New York, NY

Marcello Deraco, MD
Foundazione IRCCS Istituto Nazionale Tumori
Milan, Italy

Yuman Fong, MD
Chairman, Department of Surgery
City of Hope Cancer Center
Duarte, CA

Jan Franko, MD
Surgeon, Mercy Health Network
Des Moines, IA

Kenneth Grossman, MD
Assistant Professor, Division of Medical Oncology
University of Utah
Salt Lake City, UT

Matthew Holtzman, MD
Associate Professor of Surgery
University of Pittsburgh School of Medicine

Fabian Johnston, MD
Assistant Professor
Johns Hopkins University
Baltimore, MD

John Kane III, MD
Associate Professor of Oncology
Roswell Park Cancer Institute

Giorgos Karakousis, MD
Assistant Professor of Surgery at HUP
Perelman School of Medicine
Philadelphia, PA

Michael Kluger, MD
Assistant Professor of Surgery
Columbia University College of Physicians and Surgeons
New York, NY

Edward Levine, MD
Professor of Surgery
Wake Forest University
Winston-Salem, NC

J. Andrea McCart, MD
University of Toronto
Toronto, Ontario, Canada

Garrett Nash, MD
Associate Professor of Surgery
Memorial Sloan Kettering Cancer Center
New York, NY

James F. Pingpangk, MD
Associate Professor of Surgery
University of Pittsburgh Medical Center

Merrick Ross, MD
Professor of Surgery
Chief, Melanoma Section
University of Texas MD Anderson Cancer Center
Houston, TX

Joseph Skitzki, MD
Associate Professor of Surgery
Roswell Park Cancer Institute
Buffalo, NY

Charles Staley, MD
Emory University School of Medicine
Atlanta, GA

Paul Sugarbaker, MD
MedStar Washington Hospital Center
Washington, DC

Carlos Chan, MD
University of Iowa
Iowa City, IA

Ea-sle Chang, MD
St. Louis University Hospital
St. Louis, MO

Julius Chaprio, MD
Yale University School of Medicine
New Haven, CT

Konstantinos Chouliaras, MD
Wake Forest University
Winston-Salem, NC

Jessica Cintolo-Gonzalez, MD
Massachusetts General Hospital
Boston, MA

Joa Beane, MD
Indiana University School of Medicine
Indianapolis, IN

Tyler Bernaiche, MD
Department of Surgery
Inova Fairfax Medical Campus
Falls Church, VA

Lana Bijelic, MD
Inova Schar Cancer Institute
Falls Church, VA

Danielle Bischof, MD
Mt. Sinai Medical Center
Toronto, Ontario, Canada

Brian Boone, MD
University of Pittsburgh Medical Center

Rushin Brahmbhatt, MD
University of Pittsburgh Medical Center

Darren Bryan, MD
The University of Chicago
Department of Surgery
Chicago, IL

All individuals in a position to control the content of this education activity are required to disclose all relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

Faculty reside in the Pittsburgh, Pennsylvania, metropolitan area unless indicated otherwise.

The University of Pittsburgh is an affirmative action, equal opportunity institution.
Registration Information

Online Registration is accepted until February 14, 2017. After this date, you are only able to register for the conference on site.

Registering online is the quickest and easiest way to reserve your space at CCEHS conferences.

Visit our online registration site at http://ccehs.upmc.edu. Scroll down to the Twelfth International Symposium on Regional Cancer Therapies section on the web page.

- Click the registration button and enter all of the requested information.
- After registering, an electronic confirmation will be sent to the email address you provided when you registered.

Registration is not complete until you receive the confirmation email for your preregistration. If you do not receive this letter within 5-7 days of registration, please contact Maureen Hewko at (412) 623-5993.

You must bring this confirmation with you to the conference.

Registration Cancellation

All cancellations must be in writing and sent to us via US mail, email or fax. Tuition cancellations postmarked or date stamped before February 11, 2017 will be completely refunded. After February 11, 2017, a $35 administrative fee will be assessed. No refunds will be made after February 18, 2017.

Conference contact for cancellation requests:
Maureen Hewko, MBA
UPMC Cancer Pavilion 413, 5150 Centre Avenue
Pittsburgh, PA 15232
Email: hewkom@upmc.edu  •  Telephone: (412) 623-5993
Fax: (412) 692-2520

Registration Fees

$350 Physicians and researchers
$250 Nurses and other health care professionals
$250 Presenters

Registration fee includes:
- Continuing education credit
- Registration and course materials
- Continental breakfast, refreshments and a light dinner.

Meeting Location

The conference will be held at the Snowbird Ski and Summer Resort, Cliff Lodge, 9320 South Cliff Lodge Drive, Snowbird, UT 84092. Conference reservations are at the sole responsibility of the attendees who may contact the hotel. If registering for a room at the hotel online, please go to UPMC Cancer Therapies Program.

If you wish to make your reservation by phone, please call 1-800-453-3000 or 801-933-2222 before January 4, 2017 and ask for the University of Pittsburgh room block.

Accommodations

Nightly Guest Room Rates

$299 per night — a minimum of three nights is required for this rate. Two of the nights will be charged to your credit card at the time the reservation is made.

Note: Resorts room rates are subject to additional taxes and resort fees as applicable.

Transportation

The hotel recommends Canyon Transportation, a convenient shuttle servicing Salt Lake International Airport, Little Cottonwood Canyon and elsewhere in the Salt Lake Valley. Make shuttle reservations through Snowbird’s Central Reservations by calling 800-453-3000.

The shuttles can be arranged up until 2 days of arrival date. The fee is $72.00 round trip per adult and children 12 and under are $48.00 round trip. Booking this service requires the flight details and pre-payment with a 72 hour cancel notice. Private SUV’s and Vans can also be arranged for additional fee.

If you chose to rent a car, please pick a vehicle with four wheel drive or an SUV.

For additional information, contact:

Maureen Hewko, MBA
Telephone: (412) 623-5993
Fax: (412) 692-2520
Email: hewkom@upmc.edu
Koch Center Website: http://www.regionaltherapies.com